The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding cytokine-targeting therapies. With an established efficacy in treating both bio-naïve and bio-experienced patients, and the increased flexibility in administration routes (intravenous vs subcutaneous), the growing class of distinctive IL-23 targeting agents amplifies the importance of clinicians utilizing the most current research and guidelines when determining with patients where to best position IL-23 agents in the treatment of their IBD. In this CME Outfitters recorded symposium, faculty will examine how pro-inflammatory cytokines drive inflammation in the pathogenesis of IBD, explore the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis, and discuss the clinical implications of anti IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23 producing cells.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2025-05-31 05:00:00
- End Date: 2025-05-31 05:00:00
- Credit Details: IPCE Credits: 1.5 hours
AAPA Category 1 Credit™️: 1.5 hours
AMA PRA Category 1 Credit™️: 1.5 hours
Nursing: 1.5 hours - MOC Credit Details: ABIM - 1.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Janssen (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Gastroenterology, Internal Medicine